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Objective. Proinflammatory cytokines such as interleukin-1 (IL-1) are found in elevated levels in diseased or injured tissues and promote rapid tissue degradation while preventing stem cell differentiation. This study was undertaken to engineer inflammation-resistant murine induced pluripotent stem cells (iPSCs) through deletion of the IL-1 signaling pathway and to demonstrate the utility of these cells for engineering replacements for diseased or damaged tissues.
Methods. Targeted deletion of the IL-1 receptor type I (IL-1RI) gene in murine iPSCs was achieved using the RNA-guided, site-specific clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome engineering system. Clonal cell populations with homozygous and heterozygous deletions were isolated, and loss of receptor expression and cytokine signaling was confirmed by flow cytometry and transcriptional reporter assays, respectively. Cartilage was engineered from edited iPSCs and tested for its ability to resist IL-1-mediated degradation in gene expression, histologic, and biomechanical assays after a 3-day treatment with 1 ng/ml of IL-1a.
Results. Three of 41 clones isolated possessed the IL-1RI
1/2 genotype. Four clones possessed the IL-1RI
2/2 genotype, and flow cytometry confirmed loss of IL-1RI on the surface of these cells, which led to an absence of NFkB transcription activation after IL-1a treatment. Cartilage engineered from homozygous null clones was resistant to cytokine-mediated tissue degradation. In contrast, cartilage derived from wild-type and heterozygous clones exhibited significant degradative responses, highlighting the need for complete IL-1 blockade.
Conclusion. This work demonstrates proof-ofconcept of the ability to engineer custom-designed stem cells that are immune to proinflammatory cytokines (i.e., IL-1) as a potential cell source for cartilage tissue engineering.
Recent progress in the field of regenerative medicine has allowed the development of approaches for restoring the function of a broad range of damaged or diseased tissues, such as skin, bladder, reproductive organs, vascular grafts, and lungs (1) (2) (3) . However, there is still the challenge of controlling how engineered tissue substitutes or cell therapies respond to the environment of the transplant host. For example, engineered tissues are often implanted in the body in sites characterized by high levels of inflammation due to the underlying disease or injury, potentially leading to stem cell dysfunction. Therefore, developing technologies to precisely govern how a cell therapy or engineered tissue interprets cues from the environment of the recipient may be critical to the long-term success of regenerative medicine.
Major advances in the fields of synthetic biology and genome editing have enabled the facile and highly specific engineering of cellular genomes, opening the possibility of precise modification of stem cells at the genomic level. Programmable nucleases based on the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system provide a promising platform for introducing specific, predetermined modifications to chromosomal loci of living cells (4) (5) (6) . In this RNA-guided nuclease system, a user-defined guide RNA (gRNA) directs the endonuclease Cas9 to a specific genomic target, where it cleaves chromosomal DNA. This cleavage activates endogenous cellular DNA repair pathways and can be exploited to facilitate correction, disruption, or deletion of genes. Engineered nucleases hold great promise for regenerative medicine applications in the area of cell therapy and tissue engineering, since they provide the unique capacity to engineer customized stem cells with user-specified characteristics (7) .
Osteoarthritis (OA) is a progressive disease of synovial joints characterized by the destruction of articular cartilage and other joint tissues. While the pathogenesis of OA is not fully understood, increasing evidence suggests that proinflammatory cytokines play an important role in the onset and progression of OA (8, 9) . Other than total joint replacement with a prosthetic implant, few disease-modifying therapies are available for cartilage injury or OA. Thus, there is increasing interest in tissue engineering as a therapeutic approach for focal cartilage defects as well as total joint resurfacing (10,11). However, chondrocytes or stem cells in injured or OA joints are subjected to increased levels of proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-17, and tumor necrosis factor (TNF) (12) . The activity of these cytokines leads to increased production of matrix metalloproteinases (MMPs), aggrecanases, inducible nitric oxide synthase, and prostaglandin E 2 (PGE 2 ) (8, 12, 13) . These and other factors ultimately lead to suppression of cartilage-specific genes such as type II collagen a1 chain, down-regulation of proteoglycan levels, degeneration of the extracellular matrix (ECM), and chondrocyte apoptosis (12, 14) . Furthermore, inflammatory signaling mediated by IL-1 inhibits chondrogenic differentiation of stem cells and results in rapid degradation of stem cell-derived cartilage (15) (16) (17) (18) (19) , suggesting that implantation of engineered tissue replacements in a diseased or injured joint may significantly compromise their potential for success.
To mitigate these effects, gene therapy has been used to ectopically overexpress soluble cytokine antagonists such as IL-1 receptor antagonist (IL-1Ra) with some success (20) . A strategy for developing tissue-engineered constructs that are innately resistant to cytokine-induced degradation would be an important advance in the area of orthopedic tissue engineering and regenerative medicine.
The goals of this study were to engineer "designer" induced pluripotent stem cells (iPSCs) with specific genomic modifications that confer resistance to IL-1-mediated inflammation and to evaluate the potential of these stem cells as a source for cartilage tissue engineering and regenerative medicine. Owing to their substantial proliferative capacity and their potential to differentiate into a variety of terminal cell types, iPSCs are an attractive cell source for personalized regenerative medicine and the modeling of multifactorial diseases such as OA (21) . In this study, we used CRISPR/Cas9 to generate murine iPSCs deficient in IL-1 receptor type I (IL-1RI), the ligand-binding receptor responsible for IL-1 recognition that is necessary for IL-1 signal transduction. We then evaluated the ability of these cells to synthesize a cartilaginous ECM and resist the inflammation-mediated catabolism initiated by IL-1a.
MATERIALS AND METHODS
Induced pluripotent stem cell derivation and culture. Murine iPSCs were derived and cultured as previously described (22 (6) . Target sequences flanking exon 2 of IL-1RI and corresponding to 5 0 -GCTTCTGTGTTGAAGACTCA-3 0 and 5 0 -GTAGCTGTGGGCCCACAACC-3 0 were selected to generate the deletion of the IL-1RI signal peptide sequence. To produce single chimeric gRNA expression vectors, complementary oligonucleotides containing each of the target sequences were hybridized, phosphorylated, and cloned into an expression vector (23) (Addgene plasmid no. 47108) using a human U6 promoter. Prior to transfection, iPSCs were trypsinized and subjected to a 30-minute feeder subtraction. Lipofectamine 2000 (Life Technologies) was used according to the manufacturer's instructions to cotransfect 400 ng of each gRNA plasmid and 800 ng of hCas9 plasmid into 100,000 iPSCs freshly plated on mouse embryonic fibroblasts (MEFs) in complete, antibiotic-free iPSC medium in a 24-well plate. Cells were then subcultured on MEFs prior to single-cell deposition. In preparation for single-cell deposition, iPSCs were subjected to feeder subtraction prior to overnight culture on 0.1% gelatin. Cells were then trypsinized and subjected to a final feeder subtraction and suspended in calcium-and magnesium-free phosphate buffered saline (PBS), 1 mM EDTA, 25 mM HEPES, and 1% fetal bovine serum (FBS). A FACSVantage flow cytometer (Becton Dickinson) was used to deposit individual cells into gelatincoated wells of a 96-well plate. Clones were subcultured on gelatin for 1 additional passage to allow for screening for the appropriate deletion via genomic polymerase chain reaction (PCR) using the following primer pair: IL-1RI determination forward 5 0 -TCATCTCCTGGTTAGTTATGGTATC-3 0 and IL-1RI determination reverse 5 0 -CCGAGGCCAATGAGATTAAG-3 0 . A subset of each clone was lysed using QuickExtract (Epicentre Technologies) according to the manufacturer's instructions. The cell lysate was then diluted 8-10-fold prior to use as a template in a PCR using Q5 polymerase (New England Biolabs) according to the manufacturer's instructions with the following cycling parameters: initial denaturation at 988C for 30 seconds followed by 40 cycles of denaturation at 988C for 8 seconds, annealing at 688C for 10 seconds, and extension at 728C for 20 seconds followed by a final extension at 728C for 2 minutes. Clones of interest exhibiting the IL-1RI
1/1 , IL-1RI
, and IL-1RI 2/2 genotypes were passaged on MEFs, and culture was expanded in preparation for micromass culture.
Micromass predifferentiation culture. The iPSCs were subjected to a 15-day, high-density micromass culture as previously described (22) to achieve differentiation toward a mesenchymal state (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39982/abstract). Predifferentiated cells were subsequently cultured in medium consisting of high-glucose Dulbecco's modified Eagle's medium (DMEM), 10% FBS, nonessential amino acids, 2-mercaptoethanol (2-ME), ITS1 (insulin-transferrin-selenium) premix supplement (BD Biosciences), 25 ng/ml gentamicin, 50 mg/ml L-ascorbic acid-phosphate, 40 mg/ml L-proline, and 4 ng/ml basic fibroblast growth factor (Roche) and used in monolayer assays for functional IL-1RI protein or in cartilage tissue engineering experiments evaluating the utility of these cells as a source for regeneration of tissues immune to IL-1-mediated tissue degradation.
Flow cytometric analysis. Predifferentiated cells were trypsinized, washed in PBS, and resuspended in PBS with 1% FBS supplemented with 5 mg/ml anti-mouse CD16/32 (BioLegend) to block nonspecific immunolabeling. Cells were then immunolabeled with either a phycoerythrin-conjugated Armenian hamster anti-mouse CD121a monoclonal antibody (JAMA-147) or an isotype control (BioLegend). Cells were washed 3 times and then subjected to flow cytometry to determine the presence or absence of IL-1RI.
NF-kB activity assay. A lentiviral construct containing 5 tandem repeats (5 0 -GGAAATTCCCGGAAAGTC-CCCGGAAATTCCCGGAAAGTCCCCGGAAATTCCC-3 0 ) of NF-kB response elements upstream of a firefly luciferase gene was generated by cloning this repeat sequence upstream of the minimal cytomegalovirus promoter in pGL3Basic (Promega) and then subcloning the cassette into a lentiviral expression vector. Lentivirus was generated by cotransfecting 4 mg of the transfer vector, 3 mg of psPAX2 (Addgene catalog no. 12260), and 1.2 mg of pMD2G (Addgene catalog no. 12259) into 293T cells at confluence in the well of a 6-well plate using Lipofectamine 2000. The next day, medium from 293T lentivirus producer cells was changed, and conditioned medium containing lentivirus was collected 36 and 60 hours after transfection. The lentiviral supernatant was filtered through 0.45 mm of cellulose acetate filters and stored at 2808C until used.
Predifferentiated cells were transduced by supplementing culture medium 1:1 with viral supernatant as well as 4 mg/ml Polybrene and incubating the cells in the presence of the virus overnight. Transduced cells were expanded, passaged, and then treated with IL-1a (R&D Systems). At the indicated time points, samples were lysed and assayed for luminescence using a BrightGlo luminescence kit (Promega) according to the manufacturer's instructions. Luminescence normalized to background levels in untreated cells was used to report induction of NF-kB transcription activity.
Chondrogenesis in aggregate culture system. Passage-2 predifferentiated cells were trypsinized and resuspended in differentiation medium (high-glucose DMEM, nonessential amino acids, 2-ME, ITS1 premix supplement, 25 ng/ml gentamicin, 50 mg/ml L-ascorbic acid-phosphate, and 40 mg/ml Lproline) supplemented with 100 nM dexamethasone and 10 ng/ml transforming growth factor b3 (TGFb3; R&D Systems) at a density of 1 3 10 6 cells/ml. Aggregate cultures were produced by placing 250,000 cells in each well of a roundbottomed 96-well plate. Cells were pelleted and cultured for 27 days prior to inducing an inflammatory assault using an established in vitro OA model (18) . On day 27, cells were cultured in chondrogenic medium lacking the anabolic factors dexamethasone and TGFb3 and supplemented with 1 ng/ml IL-1a. Control aggregates received no IL-1a. Three days later, pellet cultures and culture supernatant samples were harvested for biochemical, gene expression, and histologic analyses.
Biochemical analyses. Samples used for biochemical analyses were harvested, rinsed with Dulbecco's PBS (DPBS), and stored at 2208C until testing. Pellet culture samples were digested in papain (125 mg/ml; Sigma) at 658C overnight. Digested samples were then analyzed using the PicoGreen assay (Life Technologies) to measure double-stranded DNA, the orthohydroxyproline assay for measuring total collagen content, and the dimethylmethylene blue (DMMB) assay for measuring the total sulfated glycosaminoglycan (sGAG) content of constructs (n 5 4-6 per group).
Gene expression. Samples for gene expression analysis were harvested, rinsed in DPBS, and frozen at 2808C until further processing. Total RNA was isolated according to the recommendations of the manufacturer (Norgen Biotek) following tissue homogenization with a pestle. Reverse transcription was performed using the superscript VILO complementary 
DNA synthesis kit (Life Technologies) per the manufacturer's instructions. Quantitative reverse transcription-PCR (RT-PCR) was performed with 4 samples per group on a StepOnePlus system using Power SYBR (Applied Biosystems) per the manufacturer's instructions. Cycling parameters were initial denaturation at 958C for 10 minutes followed by 40 cycles of denaturation at 958C for 15 seconds and 608C annealing and extension for 60 seconds. Fold changes were determined relative to a reference group cultured without IL-1a and by using 18S ribosomal RNA as a reference gene. Gene expression was probed using the primer pairs listed in Table 1 . Histologic processing. Samples for histology and immunohistochemistry were rinsed in DPBS upon harvest, fixed in 4% paraformaldehyde for 24 hours, paraffin embedded, and sectioned at 10 mm thickness. Cartilage pellets were stained with Safranin O-fast green/hematoxylin using standard protocols.
Analyses of culture supernatants. Medium samples were analyzed for catabolic byproducts, including nitric oxide, PGE 2 , sGAG, and MMP activities. At the time of tissue harvest, cell-conditioned medium samples (n 5 4) were collected and stored at 2208C until analysis. As with biochemical samples, sGAG in medium samples was assessed using the DMMB assay. MMP activity was assessed as previously described (24) . Briefly, after activating latent MMPs in supernatants with p-APMA, total specific MMP activity was measured as the difference in fluorescence arising from cleavage of a quenched fluorogenic substrate (DAB-Gly-Pro-Leu-Gly- Met-Arg-Gly-Lys-Flu; Sigma) in samples incubated with a broad-spectrum MMP inhibitor, GM6001, and a scrambled negative control peptide (EMD Biosciences). Nitric oxide and PGE 2 were assayed using commercially available kits (R&D Systems) following the manufacturer's instructions.
Statistical analysis. Statistical analysis was performed in the Statistica 7 software package using analysis of variance with Fisher's protected least significant difference post hoc test with a 5 0.05. For quantitative RT-PCR comparisons, fold change values were log-transformed prior to statistical analysis. The mean 6 SEM was calculated on a logarithmic scale prior to transforming data to linear values for reporting fold changes.
RESULTS
Clonal isolation and confirmation of IL-1RI functional deficit. Our strategy for targeted disruption of IL-1-mediated degradation is illustrated in Figure 1 . Two gRNAs were designed to target Cas9 to sites flanking exon 2 of the IL-1RI gene ( Figure 1B) . Such targeting of the programmable CRISPR/Cas9 nuclease results in the generation of double-strand breaks flanking the signal peptide sequence of IL-1RI in a subset of alleles. Repair of the resultant double-strand breaks via the nonhomologous end-joining pathway results in excision of the signal peptide sequence for both annotated IL-1RI isoforms ( Figure 1C) .
Plasmids encoding S pyogenes Cas9 and gRNAs specific to targets flanking exon 2 of IL-1RI were cotransfected into murine iPSCs, and 41 clones were subsequently isolated and screened after single-cell deposition. Of these, 3 were found to possess the IL-1RI 1/2 genotype, while 4 possessed the IL-1RI 2/2 genotype (Figure 2A ). Sanger sequencing of the PCR product from the IL-1RI 2/2 clones verified the expected deletion of ;790 bp ( Figure 2B ). However, in select clones that underwent chondrogenic differentiation, low but consistent expression of IL-1RI was detected on the surface in the wild-type population ( Figure 2C ). The IL-1RI 1/2 population also displayed low levels of expression, with roughly half the intensity of IL-1RI
1/1 cells, demonstrating reduced expression of IL-1RI protein after editing of 1 allele. Cells possessing the IL-1RI 2/2 genotype lacked positive staining for IL-1RI ( Figure  2C ). Absence of IL-1RI on the cell surface resulted in a functional deficiency, as indicated by a decrease in NF-kB transcription activity in IL-1RI 1/2 cells and loss of NF-kB induction in IL-1RI 2/2 cells after IL-1a stimulation, as measured in a luminescence transcriptional reporter assay ( Figure 2D ).
Cartilage engineered from CRISPR/Cas9-edited murine iPSCs is protected against IL-1a. Gene expression assays demonstrated that IL-1a (1 ng/ml) induced significant up-regulation of catabolic gene products and markers of inflammation in engineered cartilage pellets derived from cells with intact IL-1RI (Figure 3 ). CCL2 and IL-6, soluble mediators of OA and sentinel markers of inflammation, were elevated .50-fold at 72 hours in the IL-1RI
1/1 and IL-1RI 1/2 pellets (P , 10
26
). Expression of catabolic enzymes responsible for cartilage matrix degradation, such as ADAMTS-4, ADAMTS-5, , and IL-1RI
2/2 cells after 24 hours of treatment with 1 ng/ml of IL-1a. Bars show the mean 6 SEM (n 5 4 samples per group). Groups not sharing the same letter are significantly different (P , 0.05). RLU 5 relative luminescence units.
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MMP-9, and MMP-13, were also significantly upregulated in these cartilage pellets (P , 0.007). Expression of Elf-3, a transcription factor that up-regulates IL-1-induced genes such as MMP-13 (25) and suppresses type II collagen expression after cytokine treatment (14) , demonstrated a similar response (P , 10
26
). This corresponded to a concomitant reduction in type II collagen a1 chain expression in the same pellets after IL-1a treatment (P , 10
). Furthermore, expression of aggrecan, a proteoglycan critical for cartilage function, was suppressed after IL-1a treatment in IL-1RI
). In sharp contrast, none of these soluble markers of inflammation (P . 0.30), catabolic enzymes (P . 0.12), or proinflammatory transcription factors (P . 0.64) were significantly altered in pellets generated from the IL-1RI 2/2 cells. Moreover, the expression of matrix proteins type II collagen a1 chain and aggrecan was not significantly changed by IL-1a treatment in these pellets (P . 0.07) (Figure 3) .
Consistent with the observed changes at the level of transcription (Figure 3) , treatment with IL-1a resulted in an altered biochemical composition of cartilage aggregates generated from the IL-1RI
1/1 and IL-1RI 1/2 genotypes. Treatment with IL-1 had no effect on DNA content in aggregates ( Figure 4A ). Interestingly, DNA content in IL-1RI 1/2 pellets was significantly higher than DNA content in pellets derived from IL-1RI
1/1 or IL-1RI 2/2 cells irrespective of treatment, possibly due to a higher level of proliferation or cell survival in the clone chosen for these experiments. Concomitant with this increased DNA content, aggregates derived from IL-1RI 1/2 cells displayed increased accumulation of sGAG and total collagen (Supplementary Figures 1A and B , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.39982/abstract). Despite this increased accumulation, IL-1RI 1/2 -derived cartilage remained highly responsive to IL-1a. Sulfated GAG content was found to be significantly dependent on IL-1a treatment and genotype, with cartilage derived from IL-1RI
1/1 or IL-1RI 1/2 clones losing .65% of sGAG (Supplementary Figure 1A) or sGAG per microgram DNA (P , 10 26 ) ( Figure 4B ). Cartilage engineered from CRISPR/Cas9-edited IL-1RI 2/2 cells was completely protected against IL-1a, with no significant difference in sGAG or sGAG per microgram DNA content associated with IL-1a treatment (P . 0.95). No significant effects of IL-1a were found for total collagen or total collagen per microgram DNA (Supplementary Figures 1B and C) , consistent with previous studies (26) and possibly due to the retention of partially degraded, large macromolecular constituents from enzymatically degraded tissue (18) .
Histologic assessment supported the changes observed in matrix composition in biochemical analyses ( Figure 4C) . A GAG-rich matrix developed in all genotypes after maturation of engineered cartilage. As suggested by the biochemical data, larger pellets developed from IL-1RI 1/2 cells. However, a marked reduction in Safranin O , or IL-1RI 2/2 murine cells are shown. Bars show the mean 6 SEM (n 5 6 samples per group). In A, * 5 P , 0.05, versus the IL-1RI
1/1 and IL-1RI 2/2 genotypes. In B, groups not sharing the same letter are significantly different (P , 0.05). C, Representative images of Safranin O-fast green/hematoxylin staining of 10-mm sections of engineered cartilage treated with control or with 1 ng/ml of interleukin-1 (IL-1) for 72 hours. Bar 5 500 mm. Color figure can be viewed in the online issue, which is available at http:// onlinelibrary.wiley.com/journal/doi/10.1002/art.39982/abstract. staining for sGAG was observed in aggregates with intact IL-1RI after IL-1a treatment, consistent with the biochemical measurement of loss of sGAG for both IL-1RI
1/1 and IL-1RI 1/2 -derived aggregates. In contrast, the cartilage tissues engineered with the IL-1RI 2/2 cells showed no histologic changes in response to IL-1a treatment.
Culture media collected from IL-1RI 1/1 and IL-1RI 1/2 samples displayed increased levels of matrix macromolecules, degradative enzymes, and proinflammatory mediators after a 72-hour treatment with IL-1a, whereas media collected from IL-1RI 2/2 samples exhibited no signs of tissue degradation or response to IL-1a ( Figure 5 ). Specific MMP activity was significantly elevated in media collected from IL-1a-treated IL-1RI
1/1 and IL-1RI 1/2 aggregates ( Figure 5A ), likely contributing to the elevated levels of sGAG detected in the same medium samples ( Figure 5B ). The accumulation of significantly higher levels of sGAG in these samples is consistent with the observed loss of sGAG in engineered cartilage derived from IL-1RI 1/1 and IL-1RI 1/2 cells. Furthermore, the higher levels of PGE 2 and total nitric oxide species found in IL-1RI
1/1 and IL-1RI 1/2 samples ( Figures 5C and D) are indicative of the proinflammatory response of IL-1RI-competent cells to IL-1a, whereas IL-1a had no effect on cartilage derived from IL-1RI 2/2 cells.
DISCUSSION
The findings of this proof-of-concept study show the utility of CRISPR/Cas9-based programmable nucleases for applications in tissue engineering and regenerative medicine by developing stem cells with customized properties via genome engineering. Using targeted gene-editing nucleases, we engineered pluripotent stem cells with the user-specified trait of IL-1 resistance by deleting the IL-1RI signal peptide sequence. CRISPR/Cas9-mediated editing of the IL-1RI locus resulted in complete loss of IL-1 signaling by all measures evaluated. Importantly, cartilage derived from CRISPR/Cas9-edited iPSCs displayed the capacity to withstand treatment with 1 ng/ml of IL-1a. Consistent with our findings, previous studies have shown that treatment with 1 ng/ml of IL-1a results in severe degradation of both engineered cartilage derived from IL-1RI-expressing cells and cartilage from mouse explants (17, 18, 26) . However, in our study, engineered tissue derived from IL-1RI 2/2 cells was protected against OA in an in vitro model. Taken together, these results indicate that genome editing can provide a highly effective tool for generating stem cells with custom-designed properties pertinent to tissue regeneration, maintenance, and repair.
In the present study, we examined the effects of IL-1a, but not IL-1b, on engineered stem cells. Primary chondrocytes show higher sensitivity to IL-1a than to IL-1b, possibly due to differences in binding affinity to IL-1RI and/or to the decoy receptor IL-1RII (27) . It is important to note that IL-1RI expressed on the cell surface mediates signaling from both proteins, and loss of surface-expressed IL-1RI would be expected to abolish signaling from IL-1a and IL-1b (28) . Furthermore, overcoming the proinflammatory effects of not only IL-1, but also TNF, IL-6, and IL-17, and other proinflammatory factors (12, 29) represents an important challenge for regenerative medicine. Due to the pleiotropic roles of these cytokines and their involvement in tissue homeostasis, use of antagonistic therapies can lead to significant side effects (30, 31) . Our goal in this study was to explore avenues for implementing genome engineering technologies to address the challenges presented by the multifaceted proinflammatory niche. To combat the broad panel of factors driving inflammation but also essential for re-establishing homeostasis during tissue repair, future research will need to examine more sophisticated means of delivering cell-based anticytokine therapies.
Targeted genome-editing nucleases, including the CRISPR/Cas9 system used in this study as well as zinc-finger nucleases and transcription activator-like effector nucleases, have been extensively characterized for use in gene and cell therapy (7, 32, 33) , and clinical trials have demonstrated the safety and feasibility of transplanting autologous, genome-edited CD41 T cells (34) . By demonstrating the feasibility of stem cell customization to achieve desired features for regenerative medicine, our work extends previous studies exploring the wide utility of programmable nucleases as well as work evaluating the effects of targeted deletions of genes in the IL-1 family. Our findings from knockout of the IL-1RI signal peptide sequence are consistent with a previous study demonstrating the role of IL-1RI in IL-1 signal transduction (28) , in which IL-1RI-deficient mice generated by deletion of the signal peptide sequence failed to respond to IL-1, though the mice developed normally and were able to maintain homeostasis.
Interestingly, larger pellets developed in cartilage derived from IL-1RI
1/2 cells compared with that in cartilage derived from wild-type or IL-1RI 2/2 cells. Though we did not investigate this further, we attribute this effect to clonal variability, which has been reported to play a role in influencing cellular proliferation (35) . Importantly, previous investigations have also shown that IL-1RI 2/2 mice display no deficits in lymphoid or hematopoietic cell numbers and continue to exhibit normal immune functions with respect to IL-1RI-independent signaling (28, 36) . Taken together, our findings and previous findings support the utility of CRISPR/Cas9-mediated IL-1RI-knockout for targeted cell and tissue engineering therapy.
The CRISPR/Cas9 system provides an attractive platform for editing mammalian genomes due to high levels of efficiency for generating double-strand breaks at target sites and the ease with which sequence specificity of Cas9 can be reprogrammed with a new gRNA. Our results showed that genome editing with CRISPR/ Cas9 yielded the desired genomic modification in .10% of isolated clones in an unselected population. This method allows for site-specific gene deletion independent of targeting donor vectors that harbor gene traps or loxP sites that facilitate subsequent Cremediated excision. Thus, this approach overcomes the need for ectopic overexpression of selectable markers or Cre recombinase, and allows for direct, efficient gene editing.
In addition to these features, recent characterization of CRISPR/Cas9-mediated genome engineering indicates that nuclease activity is highly specific, even in human pluripotent stem cells (37, 38) . Those studies have shown that off-target mutagenesis occurs at a rate similar to or below that which accumulates simply by serial passaging of unedited cells. Moreover, significant strides have been made toward engineering improved specificity to the Streptococcus pyogenes CRISPR/Cas9 system (7), without drastic reductions in targeting efficiency. Such methods involve dual nickase versions of CRISPR/Cas9, the use of truncated gRNAs, the development of catalytically inactive Cas9 fused with RNAguided FokI nucleases, and engineered variants of Cas9 with enhanced specificity. Use of these techniques has reportedly decreased off-target activity to undetectable levels in some experiments. Though we did not take advantage of these features in the present study, we anticipate that such developments will make the use of designer nucleases even more attractive for regenerative medicine and tissue engineering applications.
The approach of site-specific genome engineering of stem cells not only opens new avenues for conferring user-specified traits such as IL-1 resistance to cells for functional tissue engineering and regenerative medicine, but also may prove complementary to earlier attempts to combat IL-1 in an arthritic joint. Promising approaches from previous work include the use of the competitive antagonist IL-1Ra via protein delivery (39, 40) . Other strategies entail ectopic overexpression of IL-1Ra by viral delivery to cells within the synovial joint, by transplantation of cells genetically engineered for constitutive overexpression of IL-1Ra, or by incorporation of IL-1Ra gene delivery vehicles in tissue engineering scaffolds designed for implantation into joint defects (17, 20) . Existing data suggest that these approaches hold great promise when the presence of IL-1Ra is sufficient to combat pathologic levels of IL-1, which may prove challenging if the transplanted cells or engineered tissues remain susceptible to high levels of IL-1 signaling. However, an important advantage of the current genome editing approach is that the modifications to the stem cell population are precise, as compared to random genomic insertions associated with viral gene therapy. In this regard, not only are IL-1RI
2/2 cells protected against IL-1 signaling, they also may provide a basal system for a cell-based drug delivery platform through additional engineered genetic modifications, including overexpression of anabolic factors (41) (42) (43) or inducible expression of antiinflammatory agents such as IL-4, IL-10, or IL-1Ra (17, 44) .
An alternative approach to attenuating IL-1RI signal transduction could entail use of either RNA interference (RNAi) or CRISPR interference (CRISPRi) to suppress transcription of IL-1RI. However, unlike approaches relying on RNAi, the targeted gene deletion used in this work abolishes the expression of functional gene product without the risk of toxicity associated with saturating microRNA pathways (45) . Additionally, while CRISPRi has proven effective for reducing transcription of many target genes with high specificity (46, 47) , even low levels of persistent expression of IL-1RI could result in loss of protection against IL-1 stimulation in long-term exposure experiments. The approach of targeted gene disruption abrogates this risk by generating cells with no functional copy of the IL-1RI gene.
In this study, we exploited the ability to clonally expand genome engineered murine iPSCs to show proof-of-principle utility of gene-editing nucleases in cartilage tissue engineering. Implementation of this technique in the clinical setting will require several advances, and future investigation will probe whether the techniques used here can be extended to human iPSCs (48) . Such studies will focus on reproducibly differentiating edited human iPSC clones and achieving acceptably low off-target activity of the CRIPSR/Cas9 platform using the methods discussed above. Furthermore, continued development of genome engineering reagents may eventually permit the direct editing of patient-derived mesenchymal stem cells or somatic cells in situ at modification rates adequate for a therapeutic effect, abrogating the need for clonal isolation and cell expansion of iPSCs, allowing the development of customdesigned engineered cells for tissue regeneration.
